

DAFTAR PUSTAKA

1. Mehrgou A, Akouchekian M. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. *Med J Islam Repub Iran*. 2016;1–12.
2. YKPI. *Kanker Payudara*. Yayasan Kanker Payudara Indonesia. 2015;
3. RI KK. *InfoDatin Bulan Peduli Kanker Payudara*. Jakarta; 2016.
4. Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2016;95(40):e4975.
5. Kresno SB. *Ilmu Dasar Onkologi*. 3rd ed. Jakarta: FK UI; 2011. 36-65 p.
6. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. *Breast Cancer Res*. 2011;13:215.
7. O'Brien KM, Cole SR, Tse C-K, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in The Carolina Breast Cancer Study. *Clin Cancer Res*. 2011;16(24):6100–10.
8. Yersal O. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J Clin Oncol*. 2014;5(3):412.
9. Comşa Ş, Cîmpean AM, Raica M. The story of MCF-7 breast cancer cell line: 40 Years of experience in research. *Anticancer Res*. 2015;35(6):3147–54.
10. Vissac C, De Latour MP, Communal Y, Bignon YJ, Bernard-Gallon DJ. Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status. *Clin Chim Acta*. 2002;320(1–2):101–10.
11. Faisel CTW. *Gambaran Efek Samping Kemoterapi Berbasis Antrasiklin Pada Pasien Kanker Payudara Di Rsud Dokter Soedarso Pontianak*. JKA. 2012.
12. Diessner J, Wischnewsky M, Blettner M, Häusler S, Janni W, Kreienberg R, et al. Do patients with luminal a breast cancer profit from adjuvant systemic therapy? A retrospective multicenter study. *PLoS One*. 2016;11(12):1–15.
13. Pham P Van, Vu NB, Pham VM, Truong NH, Pham TLB, Dang LTT, et al.

- Good manufacturing practice-compliant isolation and culture of human umbilical cord blood-derived mesenchymal stem cells. *J Transl Med. Journal of Translational Medicine*; 2014;12(1):1–10.
14. Paulsen F, Waschke J. Sobotta Atlas Anatomi Manusia jilid 1. 23rd ed. Brahm U, Huriawati H, Nugroho AW, Ramadhani D, editors. Jakarta: EGC; 2014. 114-117 p.
 15. Snell RS. Anatomi Klinis Berdasarkan Sistem. Sugiarto L, editor. Jakarta: EGC; 2012. 87-92 p.
 16. Snell RS, Bates S. Buku Ajar Pemeriksaan Fisik dan Riwayat Kesehatan. 8th ed. Hartono A, editor. Jakarta: EGC; 2012. 303-306 p.
 17. Mescher AL. Histologi Dasar Junqueira Teks dan Atlas. 12th ed. Dany F, editor. Jakarta: EGC; 2012. 369-401 p.
 18. Price, Sylvia A. Buku Patofisiologi Konsep Klinis Proses-Proses Penyakit. Jakarta: EGC; 2006. 1301-1303 p.
 19. Guyton, Arthur C, Jhon E. Buku Ajar Fisiologi Kedokteran. 12th ed. Jakarta: Saunders Elsevier; 2014. 1098-1099 p.
 20. Kumar V, Robbin SL, Cotran RA. Buku Ajar Patologi Volume 1. 7th ed. Jakarta: EGC; 2013. 765-770 p.
 21. Ramli M. Update Breast Cancer Management Diagnostic and Treatment. *Maj Kedokt Andalas*. 2015;38(1):40.
 22. Vuong D. Molecular classification of breast cancer. *Virchows Arch*. 2014;465:1–14.
 23. Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and Its relevance with breast tumor subtyping. Vol. 8, *Journal of Cancer*. 2017. p. 3131–41.
 24. Levenson AS, Craig J V. MCF-7: The First Hormone-responsive Breast Cancer Cell Line. *Cancer Res*. 1997;57(20):3071–8.
 25. Vantangoli MM, Madnick SJ, Huse SM, Weston P, Boekelheide K. MCF-7 human breast cancer cells form differentiated microtissues in scaffold-free hydrogels. *PLoS One*. 2015;10(8):1–20.
 26. Romagnolo DF, Papoutsis AJ, Laukaitis C, Selmin OI. Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as

- biomarkers of ER α -negative breast tumorigenesis. *BMC Cancer* [Internet]. *BMC Cancer*; 2015;15(1):1–11.
27. Giannakeas V, Narod SA. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. *Breast Cancer Res Treat*. Springer US; 2017;1–5.
 28. Halim D, Murti H, Sandra F, Boediman A, Setiawan. *Stem Cell Dasar Teori dan Aplikasi Klinis*. Jakarta: EGC; 2010. 1-5 p.
 29. Jeong J, Hong S, Gang E, Ahn C, Hwang S, Yang I. Differential Gene Expression Profiling of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells by DNA Microarray. *Stem Cell*. 2005;23:584–93.
 30. Pham P, Nguyen S, Phan N, Phan N. Roles of CD44 in Stem Cells and Cancer Stem Cells. *Res Gate*. 2010;
 31. Shen C, Chan T, Chen C, Hsu Y, Long C, Lai C. Human Umbilical Cord Matrix-Derived Stem Cells Expressing Interferon- γ Gene Inhibit Breast Cancer Cells via Apoptosis. *Oncotarget*. 2015;7(23):34172–8.
 32. Campbell NA, Reece JB, Urry LA, Michael CL, Wasserman SA, Minorsky P V. *Biologi Jilid 1*. 8th ed. Wulandari DT, editor. Jakarta: Erlangga; 2010. 352 p.
 33. Joko T, Kosumandari N, Hartono S. Optimization Of Pcr Method For The Detection Of *Pectobacterium carotovorum* ., *J Perlindungan Tanam Indones*. 2011;17(2):54–9.
 34. Nolan T, Anders Bergkvist C, Carvallo C, Peter Chereson MH, Daley L, Heath A, et al. *A Technical Guide*. Sigma-Aldrich. 2016.
 35. Yusuf ZK. *Polymerase Chain Reaction (PCR)*. Saintek. 2010;5(6).
 36. Roche. *PCR Applications Manual*. Evolution (N Y). 2006;340.
 37. Hewajuli DA, Nlpi D, Idt, Holliday DL, Speirs V, Levenson AS, et al. Perkembangan Teknologi Reverse Transcriptase-Polymerase Chain Reaction dalam Mengidentifikasi Genom Avian Influenza dan Newcastle Diseases. *Cancer Res*. 2011;24(20):1–21.
 38. Thermo Fisher Scientific. *TRIZol Reagent User Guide* - Pub. no. MAN0001271 - Rev. A.0. Vol. 15596018, User Guide. USA; 2016. p. 1–6.

39. BIO-RAD. iScript™ cDNA Synthesis Kit [Internet]. 2012. p. 4978.
40. Kachhap SK, Vetale SP, Dange P, Ghosh SN. Reduced expression of the BRCA1 gene and increased chromosomal instability in MCF-7 cell line. *Cell Biol Int*. 2001;25(6):547–51.
41. Yarden RI, Papa MZ. BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. *Mol Cancer Ther*. 2006;5(6):1396–404.
42. Karnan S, Mohseni M, Konishi Y, Tamaki A, All E. Controversial BRCA1 allelotypes in commonly used breast cancer cell lines. *Breast Cancer Res Treat*. 2010;5(4):204–11.
43. Rhodes L V., Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, et al. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. *Breast Cancer Res Treat*. 2010;121(2):293–300.
44. Lee HY, Hong IS. Double-edged sword of mesenchymal stem cells: Cancer-promoting versus therapeutic potential. *Cancer Sci*. 2017;108(10):1939–46.
45. Melzer C, Yang Y, Hass R. Interaction of MSC with tumor cells. *Cell Commun Signal. Cell Communication and Signaling*; 2016;14(1):1–12.
46. Yan Y, Haas JP, Kim M, Sgagias MK, Cowan KH. BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. *J Biol Chem*. 2002;277(36):33422–30.
47. Rhodes L V., Antoon JW, Muir SE, Elliott S, Beckman BS, Burow ME. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. *Mol Cancer. BioMed Central Ltd*; 2010;9(1):295.
48. Ryu CH, Park SA, Kim SM, Lim JY, Jeong CH, Jun JA, et al. Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways. *Biochem Biophys Res Commun. Elsevier Inc.*; 2010;398(1):105–10.
49. Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, N S, et al. Negative

regulation of AKT activation by BRCA1. *Cancer Res.* 2009;68(24):10040–4.

50. Mandel K, Yang Y, Schambach A, Glage S, Otte A, Hass R. Mesenchymal Stem Cells Directly Interact with Breast Cancer Cells and Promote Tumor Cell Growth In Vitro and In Vivo. *Stem Cells Dev.* 2013;22(23):3114–27.

